<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04986020</url>
  </required_header>
  <id_info>
    <org_study_id>2557</org_study_id>
    <secondary_id>IRAS 280243</secondary_id>
    <nct_id>NCT04986020</nct_id>
  </id_info>
  <brief_title>Identifying New Biomarkers of Parkinson's From Routine Brain Imaging</brief_title>
  <official_title>Identifying New Biomarkers of Parkinson's From Routine Brain Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Plymouth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Plymouth</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will use routine computer tomography (CT), magnetic resonance spectroscopy (MRI)&#xD;
      and nuclear medicine (NM) brain imaging data to produce new diagnostic tests for the onset of&#xD;
      Parkinson's disease. This will enable hopefully earlier diagnosis than is currently possible.&#xD;
      This will entail the analysis of anonymised CT/MRI/NM brain images collected prior to the&#xD;
      point when these subjects were diagnosed with PD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We intend to use historical CT/MRI/nuclear medicine brain scans to identify novel imaging&#xD;
      biomarkers of prodromal Parkinson's disease. The primary data source for the study will be&#xD;
      MRI and CT brain scans, whilst nuclear medicine imaging brain imaging (DAT scans) will be&#xD;
      used to validate models produced and provide a functional outcome measure of brain dopamine&#xD;
      uptake. We shall utilise a an artificial intelligence approach to compare scans of PD cases&#xD;
      with matched controls in order to identify these imaging biomarkers.&#xD;
&#xD;
      A list of participants with a diagnosis will be compiled. This list, together with relevant&#xD;
      clinical data, will be linked with historical CT/MRI/nuclear medicine scans carried out over&#xD;
      the preceding years. A control group of matched non-PD scans will also be compiled.&#xD;
&#xD;
      The dataset will be anonymised and a bespoke ML pipeline will be used to identify imaging&#xD;
      featureswhich may be indicative of prodromal PD. This initial stage will be carried out at&#xD;
      University Hospital Plymouth NHS Trust (UHPNT), the Royal Cornwall Hospital NHS Trust (RCHNT)&#xD;
      and Cornwall Partnership NHS Trust (CPNT). If successful, findings will be validated in a&#xD;
      larger sample of scans compiled from hospitals regionally and nationally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The presence of novel putative biomarkers of future PD development as defined by a deep-learning method</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson disease</arm_group_label>
    <description>Participants with a clinical diagnosis of Parkinson's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Identification of novel biomarkers from MRI</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Parkinson disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants drawn from the catchment areas of participating healthcare organisations&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - A clinical diagnosis of Parkinson's&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - No clinical diagnosis of Parkinson's&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephen Mullin, MRCP. PhD.</last_name>
    <phone>01752764487</phone>
    <email>stephen.mullin@plymouth.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Megan Courtman, MSc.</last_name>
    <phone>01752764487</phone>
    <email>megan.courtman@postgrad.plymouth.ac.uk</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Plymouth</investigator_affiliation>
    <investigator_full_name>Stephen Mullin</investigator_full_name>
    <investigator_title>Clinical Lecturer in Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 11, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT04986020/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

